Drug intelligence / Profile preview

CORDStrom

Development stage: Unknown
Lead developer: INmune Bio
Modality: Cell Therapies
Administration: Injection, Infusion

Overview

CORDStrom is an umbilical cord-derived cell therapy developed by INmune Bio for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The therapy utilizes donor materials sourced from umbilical cord tissue, secured through a long-term supply agreement with Anthony Nolan. CORDStrom has been evaluated in the Phase 2 MissionEB trial, a double-blind, randomized, placebo-controlled study in pediatric patients conducted at Great Ormond Street Hospital and Birmingham Children’s Hospital. INmune Bio is scaling up commercial-ready manufacturing in partnership with the Cell and Gene Therapy Catapult in the UK to support a planned Biologics License Application (BLA) submission to the FDA in early 2026.

Brand names: CORDStrom
Other names: CORDStrom

Beyond the preview

Go deeper on CORDStrom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CORDStrom.

Explore the full profile